<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Triamterene</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00384</strong>&#160; (APRD00079)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>A pteridine that is used as a mild diuretic. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00384/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00384/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00384.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00384.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00384.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00384.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00384.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00384">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>6-phenylpteridine-2,4,7-triamine</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>IUPAC</td></tr><tr><td>Teridin</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>IS</td></tr><tr><td>Triamteren</td><td>German</td><td>INN</td></tr><tr><td>Triamt&#233;r&#232;ne</td><td>French</td><td>DCF</td></tr><tr><td>Triamterene</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>USAN, JAN, DCIT, BAN, BP 2011, JP XV, Ph. Eur. 7, USP 34</td></tr><tr><td>Triamtereno</td><td>Spanish</td><td>INN</td></tr><tr><td>Triamterenum</td><td>Latin</td><td>Ph. Eur. 7</td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Diuteren</td><td>Kotobuki Seiyaku</td></tr><tr><td>Dyazide</td><td>Goldshield</td></tr><tr><td>Dyrenium</td><td>Wellspring</td></tr><tr><td>Dytac</td><td>Mercury</td></tr><tr><td>Riyazine</td><td>Ciiphar</td></tr><tr><td>Triteren</td><td>Kyoto Yakuhin</td></tr><tr><td>Urinis</td><td>Ying Yuan</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>Dyazide</td><td>Hydrochlorothiazide + Triamterene</td></tr><tr><td>Maxzide</td><td>Hydrochlorothiazide + Triamterene</td></tr><tr><td>MAXZIDE-25</td><td>Triamterene + Hydrochlorothiazide</td></tr><tr><td>Nu-Triazide</td><td>Hydrochlorothiazide + Triamterene</td></tr><tr><td>Penta-Triamterene HCTZ</td><td>Hydrochlorothiazide + Triamterene</td></tr><tr><td>Pro-Triazide</td><td>Hydrochlorothiazide + Triamterene</td></tr><tr><td>Riva-Zide</td><td>Hydrochlorothiazide + Triamterene</td></tr><tr><td>Triampur</td><td>Hydrochlorothiazide + Triamterene</td></tr></tbody></table></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/diuretics">Diuretics</a></li>
<li><a href="/mesh/epithelial-sodium-channel-blockers">Epithelial Sodium Channel Blockers</a></li></ul></td></tr><tr><th>CAS number</th><td>396-01-0</td></tr><tr><th>Weight</th><td>Average: 253.2626<br>Monoisotopic: 253.107593387</td></tr><tr><th>Chemical Formula</th><td>C<sub>12</sub>H<sub>11</sub>N<sub>7</sub></td></tr><tr><th>InChI Key</th><td>FNYLWPVRPXGIIP-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C12H11N7/c13-9-7(6-4-2-1-3-5-6)16-8-10(14)18-12(15)19-11(8)17-9/h1-5H,(H6,13,14,15,17,18,19)</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">6-phenylpteridine-2,4,7-triamine</div></td></tr><tr><th>SMILES</th><td><div class="wrap">NC1=NC(N)=C2N=C(C(N)=NC2=N1)C1=CC=CC=C1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Pteridines and Derivatives</td></tr><tr><th>Subclass</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Direct parent</th><td>Pteridines and Derivatives</td></tr><tr><th>Alternative parents</th><td>Aminopyrimidines and Derivatives; Pyrazines; Primary Aromatic Amines; Benzene and Substituted Derivatives; Polyamines</td></tr><tr><th>Substituents</th><td>aminopyrimidine; benzene; pyrimidine; primary aromatic amine; pyrazine; polyamine; primary amine; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the pteridines and derivatives. These are polycyclic aromatic compounds containing a pteridine moiety, which consists of a pyrimidine fused to a pyrazine ring to form  pyrimido(4,5-b)pyrazine.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and the nephrotic syndrome; also in steroid-induced edema, idiopathic edema, and edema due to secondary hyperaldosteronism.</td></tr><tr><th>Pharmacodynamics</th><td>Triamterene, a relatively weak, potassium-sparing diuretic and antihypertensive, is used in the management of hypokalemia. Triamterene is similar in action to amiloride but, unlike amiloride, increases the urinary excretion of magnesium.</td></tr><tr><th>Mechanism of action</th><td>Triamterene inhibits the epithelial sodium channels on principal cells in the late distal convoluted tubule and collecting tubule, which are responsible for 1-2% of total sodium reabsorption. As sodium reabsorption is inhibited, this increases the osmolarity in the nephron lumen and decreases the osmolarity of the interstitium. Since sodium concentration is the main driving force for water reabsorption, triamterene can achieve a modest amount of diuresis by decreasing the osmotic gradient necessary for water reabsorption from lumen to interstitium. Triamterene also has a potassium-sparing effect. Normally, the process of potassium excretion is driven by the electrochemical gradient produced by sodium reabsorption. As sodium is reabsorbed, it leaves a negative potential in the lumen, while producing a positive potential in the principal cell. This potential promotes potassium excretion through apical potassium channels. By inhibiting sodium reabsorption, triamterene also inhibits potassium excretion. </td></tr><tr><th>Absorption</th><td>Rapidly absorbed, with somewhat less than 50% of the oral dose reaching the urine.</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>55-67% (93% for the OH-TA-ester metabolite)</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Triamterene is primarily metabolized to the sulfate conjugate of hydroxytriamterene. Both the plasma and urine levels of this metabolite greatly exceed triamterene levels.</p></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td>255 minutes (188 minutes for OH-TA-ester metabolite) after IV administration.</td></tr><tr><th>Clearance</th><td><ul>
	<li>4.5 l/min [total plasma clearance]</li>
	<li>0.22 l/kg [renal plasma clearance]</li>
</ul></td></tr><tr><th>Toxicity</th><td>In the event of overdosage it can be theorized that electrolyte imbalance would be the major concern, with particular attention to possible hyperkalemia. Other symptoms that might be seen would be nausea and vomiting, other G.I. disturbances, and weakness. It is conceivable that some hypotension could occur. The oral LD<sub>50</sub> in mice is 380 mg/kg.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>1.0</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.8735</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.7017</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.6269</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8782</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8814</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8437</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8949</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.8892</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.7542</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Inhibitor</td>
        <td>0.9107</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.907</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9231</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9025</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.831</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.6161</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.8934
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9092
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9959
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.7706 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9604
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.6829
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Wellspring pharmaceutical corp</li></ul></td></tr><tr><th>Packagers</th><td><ul><li>Advanced Pharmaceutical Services Inc.</li>
<li><a href="http://www.amerisourcebergen.com">Amerisource Health Services Corp.</a></li>
<li><a href="http://www.apotex.com">Apotex Inc.</a></li>
<li>Apotheca Inc.</li>
<li><a href="http://orders.a-smeds.com">A-S Medication Solutions LLC</a></li>
<li><a href="http://www.atlanticbiologicals.com">Atlantic Biologicals Corporation</a></li>
<li>Barr Pharmaceuticals</li>
<li><a href="http://bryantranchprepack.com">Bryant Ranch Prepack</a></li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li><a href="http://www.chcsct.com">Central Texas Community Health Centers</a></li>
<li>Comprehensive Consultant Services Inc.</li>
<li><a href="http://www.corepharma.com">Corepharma LLC</a></li>
<li>Dept Health Central Pharmacy</li>
<li>DHHS Program Support Center Supply Service Center</li>
<li>Direct Dispensing Inc.</li>
<li><a href="http://www.drxdispensing.com">Dispensing Solutions</a></li>
<li><a href="http://www.dhscorp.com">Diversified Healthcare Services Inc.</a></li>
<li><a href="http://www.duramed.ca">Duramed</a></li>
<li><a href="http://www.gsk.com">GlaxoSmithKline Inc.</a></li>
<li><a href="http://www.gsms.us">Golden State Medical Supply Inc.</a></li>
<li><a href="http://www.ghc.org">Group Health Cooperative</a></li>
<li><a href="http://hjharkinscompanyinc.com">H.J. Harkins Co. Inc.</a></li>
<li>Heartland Repack Services LLC</li>
<li>Ivax Pharmaceuticals</li>
<li>Kaiser Foundation Hospital</li>
<li>Liberty Pharmaceuticals</li>
<li><a href="http://www.majorpharmaceuticals.com">Major Pharmaceuticals</a></li>
<li><a href="http://www.medvantx.com">Medvantx Inc.</a></li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li><a href="http://www.mylan.com">Mylan</a></li>
<li>Neuman Distributors Inc.</li>
<li><a href="http://www.nucarerx.com">Nucare Pharmaceuticals Inc.</a></li>
<li><a href="http://www.palmettopharm.com">Palmetto Pharmaceuticals Inc.</a></li>
<li>PCA LLC</li>
<li><a href="http://www.pdrx.com">PD-Rx Pharmaceuticals Inc.</a></li>
<li>Pharmaceutical Utilization Management Program VA Inc.</li>
<li>Pharmacy Service Center</li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.pliva.com">Pliva Inc.</a></li>
<li><a href="http://www.preferredpharmaceuticals.com">Preferred Pharmaceuticals Inc.</a></li>
<li>Prepackage Specialists</li>
<li><a href="http://www.prepaksys.com">Prepak Systems Inc.</a></li>
<li><a href="http://www.worldoftest.com">Qualitest</a></li>
<li><a href="http://www.rebelrx.com">Rebel Distributors Corp.</a></li>
<li><a href="http://www.remedyrepack.com">Remedy Repack</a></li>
<li>Resource Optimization and Innovation LLC</li>
<li><a href="http://www.sandhillspackaging.com">Sandhills Packaging Inc.</a></li>
<li><a href="http://www.sandoz.ca">Sandoz</a></li>
<li><a href="http://www.southwoodhealthcare.com">Southwood Pharmaceuticals</a></li>
<li><a href="http://www.stat-scripts.com">Stat Scripts LLC</a></li>
<li>Tya Pharmaceuticals</li>
<li><a href="http://www.udllabs.com">UDL Laboratories</a></li>
<li>Va Cmop Dallas</li>
<li>Vangard Labs Inc.</li>
<li><a href="http://www.watson.com">Watson Pharmaceuticals</a></li>
<li><a href="http://www.wellspringpharm.com">Wellspring Pharmaceutical</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Capsule</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><ul><li><a data-no-turbolink="true" href="/spectra/spectra/nmr_one_d/1818">1H NMR Spectrum</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/6328">MS/MS Spectrum CI-B (Unknown) </a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/nmr_two_d/1758">[1H,13C] 2D NMR Spectrum</a></li></ul></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00542">Benazepril</a></td><td>Increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB00796">Candesartan</a></td><td>Increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB01197">Captopril</a></td><td>Increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB01340">Cilazapril</a></td><td>Increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB01395">Drospirenone</a></td><td>Increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB00584">Enalapril</a></td><td>Increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB00700">Eplerenone</a></td><td>This association presents an increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB00876">Eprosartan</a></td><td>Increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB01342">Forasartan</a></td><td>Increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB00492">Fosinopril</a></td><td>Increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB00328">Indomethacin</a></td><td>Risk of acute renal impairment with this combination</td></tr><tr><td><a href="/drugs/DB01029">Irbesartan</a></td><td>Increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB00722">Lisinopril</a></td><td>Increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB00678">Losartan</a></td><td>Increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB00691">Moexipril</a></td><td>Increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB00790">Perindopril</a></td><td>Increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB01344">Polystyrene sulfonate</a></td><td>Antagonism of action</td></tr><tr><td><a href="/drugs/DB01345">Potassium</a></td><td>Increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB00881">Quinapril</a></td><td>Increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB00178">Ramipril</a></td><td>Increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB01347">Saprisartan</a></td><td>Increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB01348">Spirapril</a></td><td>Increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB01349">Tasosartan</a></td><td>Increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB00966">Telmisartan</a></td><td>Telmisartan may increase the hyperkalemic effect of Triamterene. Monitor for increased serum potassium concentrations during concomitant therapy.</td></tr><tr><td><a href="/drugs/DB00519">Trandolapril</a></td><td>Increased risk of hyperkalemia. Monitor serum potassium levels.</td></tr><tr><td><a href="/drugs/DB00374">Treprostinil</a></td><td>Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. </td></tr><tr><td><a href="/drugs/DB00177">Valsartan</a></td><td>Increased risk of hyperkalemia</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>